Discovery Bioanalysis
We provide a rapid fit-for-purpose bioanalytical service for in vitro and in vivo discovery studies.
We undertake quantitative LC-MS/MS analysis of drugs, metabolites and biomarkers in a range of matrices, including plasma, blood, dried blood spots (DBS), urine, bile, tissue homogenate and in vitro samples. We can provide bioanalytical data and scientific guidance to support discovery studies including PK, PKPD and exploratory toxicology.
We offer a tiered approach to bioanalysis, ranging from simple, largely generic methodologies to pre-qualified assays incorporating bespoke method development. As a minimum, our assays involve compound optimisation on the relevant mass spectrometry system, internal standard response checks, carry-over assessment, calibration curve acceptance criteria and evaluation of linearity and regression models.
Beyond the most simple tier, additional quality criteria are introduced either as a component of the standard sample assay batch or as part of a pre-qualification process. These criteria include QC samples with fit-for-purpose acceptance criteria, matrix effects, recovery and vehicle effect experiments, accuracy and precision evaluations and assessments of dilution integrity.
Using state-of-the-art instrumentation, including:
- AB SCIEX TQ 6500 mass spectrometer
- AB SCIEX API 5000 mass spectrometers
- AB SCIEX API 4000 mass spectrometers
- Agilent 1290 high-resolution LC systems
- Hamilton Microlab Star robots
We use our experience and expertise to deliver fit-for-purpose, high-sensitivity bioanalytical data in a diverse range of species and matrices with an average 3-4 working days cycle time.